Use of immune globulin to prevent symptomatic cytomegalovirus disease in transplant recipients ‐ A meta‐analysis
- 1 February 1994
- journal article
- research article
- Published by Wiley in Clinical Transplantation
- Vol. 8 (1) , 10-18
- https://doi.org/10.1111/j.1399-0012.1994.tb00935.x
Abstract
The objective of this meta‐analysis was to review the evidence for the use of immune globulin in the prevention of symptomatic cytomegalovirus (CMV) disease in transplant recipients. A computerized search of Medline from 1980 to October 1991 was conducted using the textword “cytomegalo:” and the subheading “prevention and control” for studies in all languages. Reference lists, a manual search of relevant literature and communication with internationally recognized experts were used to locate additional studies. Of the studies identified, 18 met the inclusion criteria (population: transplant recipients; intervention: immune globulin; outcome: symptomatic cytomegalovirus disease; study design: randomized controlled trial). The meta‐analysis of the 18 studies showed a reduction in the incidence of symptomatic CMV disease in the group receiving immune globulin as compared to the untreated group. The common odds ratio was 0.58 (95% C.I. 0.42 to 0.77). Analyses of combining trials by subgroups of polyvalent immune globulin, hyperimmune globulin, bone marrow recipients and solid organ recipients resulted in common odds ratios comparable to the overall common odds ratio. Common odds ratios for the trials reporting cytomegalovirus interstitial pneumonia, cytomegalovirus death, overall death and graft loss ranged from 0.47 to 0.69. Common odds ratios for the effect of immune globulin prophylaxis analyzed by pre‐transplant patient/donor cytomegalovirus antibody status ranged from 0.32 to 0.50. In conclusion, the use of immune globulin as passive immunization for the prevention of symptomatic cytomegalovirus disease in the transplant population is supported by this meta‐analysis. The response is similar in both bone marrow and solid organ transplant recipients. There appears to be no significant clinical advantage in the use of hyperimmune globulin over polyvalent immune globulin.This publication has 34 references indexed in Scilit:
- The Prevention of Cytomegalovirus Disease in Renal TransplantationAmerican Journal of Kidney Diseases, 1990
- Intravenous immune globulin prophylaxis in recipients of a marrow transplantJournal of Allergy and Clinical Immunology, 1989
- Immunoprophylaxis of cytomegalovirus infections in transplanted patientsEuropean Journal of Cancer and Clinical Oncology, 1989
- Cytomegalovirus Infection in Transplant RecipientsImmunology and Allergy Clinics of North America, 1989
- Uses of Immune Globulins in the Prophylaxis and Treatment of Viral InfectionsClinics In Laboratory Medicine, 1987
- Immunoglobulin therapy in bone marrow transplantationThe American Journal of Medicine, 1987
- Intravenous immunoglobulin for modification of cytomegalovirus infections associated with bone marrow transplantation: Preliminary results of a controlled trialThe American Journal of Medicine, 1984
- Prevention and treatment of cytomegalovirus infections with interferons and immune globulinsInfection, 1984
- Primary Cytomegalovirus and Opportunistic InfectionsJAMA, 1978
- Transmission of cytomegalovirus infection with renal allograftKidney International, 1975